(Z)-3-cyano-3-(4-hydroxyphenyl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-3-cyano-3-(4-hydroxyphenyl)prop-2-enoic acid
• 化学式: C₁₀H₇NO₃
• 分子量: 189.17
• InChiKey: OCIBJKIHKXZBPJ-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Peptides for lowering blood glucose levels
  申请人：Zealand Pharmaceuticals A/S

  公开号：EP1076066A1

  公开（公告）日：2001-02-14

  The present invention relates to novel variants that lower blood glucose levels, specific variants of exendin-4. The invention further relates to peptide conjugates that lower blood glucose levels and which have increased bioavailability.

  本发明涉及可降低血糖水平的新型变体，即 exendin-4 的特定变体。本发明还涉及可降低血糖水平且生物利用度更高的肽结合物。
• Peptides that lower blood glucose levels
  申请人：Zealand Pharma A/S

  公开号：EP1329458A2

  公开（公告）日：2003-07-23

  The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.

  本发明涉及新型多肽共轭物，它具有更高的稳定性，可用于治疗血糖过高。
• Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
  申请人：Zealand Pharma A/S

  公开号：EP1950223A2

  公开（公告）日：2008-07-30

  The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.

  本发明涉及一种药理活性肽结合物，它具有较低的酶裂解倾向，由药理活性肽序列（X）和与 X 共价结合的 4-20 个氨基酸残基的稳定肽序列（Z）组成。
• Method for the isolation and identification of ADP-ribosylated molecules
  申请人：Fondazione Telethon

  公开号：EP2073012A1

  公开（公告）日：2009-06-24

  The present invention relates to a method for the identification and/or isolation of ADP-ribosylated molecules, in particular mono-ADP-ribosylated proteins. The method makes use of molecules, namely polypeptides or proteins including macro domains as selective ligands for ADP- ribosylated molecules, and can be combined with known techniques for their identification.

  本发明涉及一种鉴定和/或分离 ADP 核糖基化分子，特别是单 ADP 核糖基化蛋白质的方法。该方法利用分子，即包括宏结构域的多肽或蛋白质，作为 ADP 核糖基化分子的选择性配体，并可与已知技术相结合，对其进行鉴定。
• Novel peptide agonists of GLP-1 activity
  申请人：Zealand Pharma A/S

  公开号：US20040106547A1

  公开（公告）日：2004-06-03

  Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.

  用于降低血糖水平的新型 GLP-1 活性肽激动剂。新型多肽包括 GLP-1 或 exendin-4 多肽序列的变体，具有药理活性和稳定性。这些多肽可用于治疗因调节过高的血糖水平和/或调节胃排空而获益的疾病，如糖尿病和进食障碍。